Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M

Viking Therapeutics, Inc.

Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.
Phase 3 VANQUISH-1 (4,500 patients) and VANQUISH-2 (1,000) for subcutaneous VK2735 fully enrolled.
Oral VK2735 Phase 3 trial initiation expected in Q4 2026; maintenance dosing data due Q3 2026.
Phase 1 trial of amylin agonist VK3019 initiated in Q2 2026 after IND clearance.
Appointed Hubert Chen, M.D., as CMO; Dorothy Gemmell to board; cash $502M at June 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.